An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)
Conditions
- Non-small Cell Lung Cancer
Interventions
Sponsor
Novartis Pharmaceuticals